Loading...

Araz Marachelian, MD

Title(s)Assistant Professor of Clinical Pediatrics
SchoolKeck School of Medicine of USC
Phone+1 323 361 8573
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    1994Undergraduate Research Award National Science Foundation
    University of California, Berkeley1995Outstanding Service Award
    University of California, Berkeley1995High Distinction of Honors
    University of California, Irvine1999Outstanding Achievement in Pediatrics and Psychiatry
    AACR/ASCO2005Clinical Trial Training Workshop Award
    2009  - 2010Southern California Super Doctors
    Pasadena Magazine2013Top Doctor
    2014Southern California Super Doctors
    2014  - 2015NCI Cancer Clinical Investigator Team Leadership Award (CCITLA)

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Pinto N, DuBois SG, Marachelian A, Diede SJ, Taraseviciute A, Glade Bender JL, Tsao-Wei D, Groshen SG, Reid JM, Haas-Kogan DA, Reynolds CP, Kang MH, Irwin MS, Macy ME, Villablanca JG, Matthay KK, Park JR. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatr Blood Cancer. 2018 Jul; 65(7):e27023. PMID: 29603591.
      View in: PubMed
    2. Matsuno R, Gifford AJ, Fang J, Warren M, Lukeis RE, Trahair T, Sugimoto T, Marachelian A, Asgharzadeh S, Maris JM, Ikegaki N, Shimada H. Rare MYC-amplified Neuroblastoma With Large Cell Histology. Pediatr Dev Pathol. 2018 Sep-Oct; 21(5):461-466. PMID: 29426276.
      View in: PubMed
    3. Villablanca JG, Ji L, Shapira-Lewinson A, Marachelian A, Shimada H, Hawkins RA, Pampaloni M, Lai H, Goodarzian F, Sposto R, Park JR, Matthay KK. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma. Pediatr Blood Cancer. 2018 May; 65(5):e26940. PMID: 29350464.
      View in: PubMed
    4. Guerra JA, Dhall G, Marachelian A, Castillo E, Malvar J, Wong K, Sposto R, Finlay JL. Marrow-ablative chemotherapy followed by tandem autologous hematopoietic cell transplantation in pediatric patients with malignant brain tumors. Bone Marrow Transplant. 2017 Nov; 52(11):1543-1548. PMID: 28783147.
      View in: PubMed
    5. Marachelian A, Villablanca JG, Liu CW, Liu B, Goodarzian F, Lai HA, Shimada H, Tran HC, Parra JA, Gallego R, Bedrossian N, Young S, Czarnecki S, Kennedy R, Weiss BD, Goldsmith K, Granger M, Matthay KK, Groshen S, Asgharzadeh S, Sposto R, Seeger RC. Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. Clin Cancer Res. 2017 Sep 15; 23(18):5374-5383. PMID: 28559462.
      View in: PubMed
    6. Secola R, Marachelian A, Cohn SL, Toy B, Neville K, Granger M, Brentlinger A, Martin G. The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy. J Pediatr Oncol Nurs. 2017 May/Jun; 34(3):160-172. PMID: 28061552.
      View in: PubMed
    7. Huibregtse KE, Vo KT, DuBois SG, Fetzko S, Neuhaus J, Batra V, Maris JM, Weiss B, Marachelian A, Yanik GA, Matthay KK. Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine. Eur J Cancer. 2016 10; 66:144-52. PMID: 27573428.
      View in: PubMed
    8. Jackson JR, Tran HC, Stein JE, Shimada H, Patel AM, Marachelian A, Kim ES. The clinical management and outcomes of cervical neuroblastic tumors. J Surg Res. 2016 07; 204(1):109-13. PMID: 27451875.
      View in: PubMed
    9. Villablanca JG, Volchenboum SL, Cho H, Kang MH, Cohn SL, Anderson CP, Marachelian A, Groshen S, Tsao-Wei D, Matthay KK, Maris JM, Hasenauer CE, Czarnecki S, Lai H, Goodarzian F, Shimada H, Reynolds CP. A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatr Blood Cancer. 2016 08; 63(8):1349-56. PMID: 27092812.
      View in: PubMed
    10. DuBois SG, Marachelian A, Fox E, Kudgus RA, Reid JM, Groshen S, Malvar J, Bagatell R, Wagner L, Maris JM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Matthay KK, Mosse YP. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. J Clin Oncol. 2016 Apr 20; 34(12):1368-75. PMID: 26884555; PMCID: PMC4872349 [Available on 02/20/17].
      View in: PubMed, PubMed Central
    11. Marachelian A, Desai A, Balis F, Katzenstein H, Qayed M, Armstrong M, Neville KA, Cohn SL, Bush M, Gunawan R, Lim AP, Smith MA, Smith LM. Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy. Cancer Chemother Pharmacol. 2016 Feb; 77(2):405-12. PMID: 26791869; PMCID: PMC4747995.
      View in: PubMed, PubMed Central
    12. Trieu M, DuBois SG, Pon E, Nardo L, Hawkins RA, Marachelian A, Twist CJ, Park JR, Matthay KK. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG). Pediatr Blood Cancer. 2016 Mar; 63(3):436-42. PMID: 26506090.
      View in: PubMed
    13. DuBois SG, Groshen S, Park JR, Haas-Kogan DA, Yang X, Geier E, Chen E, Giacomini K, Weiss B, Cohn SL, Granger MM, Yanik GA, Hawkins R, Courtier J, Jackson H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Villablanca JG, Marachelian A, Matthay KK. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2015 Jun 15; 21(12):2715-21. PMID: 25695691; PMCID: PMC4470833.
      View in: PubMed, PubMed Central
    14. Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, Park JR, Tsao-Wei D, Hawkins R, Shulkin BL, Jackson H, Goodarzian F, Shimada H, Courtier J, Hutchinson R, Haas-Koga D, Hasenauer CB, Czarnecki S, Katzenstein HM, Matthay KK. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study. Biol Blood Marrow Transplant. 2015 Apr; 21(4):673-81. PMID: 25639769.
      View in: PubMed
    15. Tran HC, Marachelian A, Venkatramani R, Jubran RF, Mascarenhas L. Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma. Pediatr Hematol Oncol. 2015 Feb; 32(1):26-31. PMID: 25551355.
      View in: PubMed
    16. Kang MH, Villablanca JG, Glade Bender JL, Matthay KK, Groshen S, Sposto R, Czarnecki S, Ames MM, Reynolds CP, Marachelian A, Maurer BJ. Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study. BMC Res Notes. 2014 Apr 23; 7:256. PMID: 24755475; PMCID: PMC4006848.
      View in: PubMed, PubMed Central
    17. Brown RJ, Rahim H, Wong KE, Cooper RM, Marachelian A, Butturini A, Dhall G, Finlay JL. Infectious complications in the first year following autologous hematopoietic progenitor cell rescue for children with brain tumors. Pediatr Blood Cancer. 2013 Dec; 60(12):2012-7. PMID: 23956157.
      View in: PubMed
    18. Maurer BJ, Kang MH, Villablanca JG, Janeba J, Groshen S, Matthay KK, Sondel PM, Maris JM, Jackson HA, Goodarzian F, Shimada H, Czarnecki S, Hasenauer B, Reynolds CP, Marachelian A. Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. Pediatr Blood Cancer. 2013 Nov; 60(11):1801-8. PMID: 23813912; PMCID: PMC4066886.
      View in: PubMed, PubMed Central
    19. Giuliani S, Marachelian A, Franklin A, Shimada H, Grikscheit T. Forearm skeletal muscle neuroblastoma in a child: a rare primary location. J Pediatr Hematol Oncol. 2013 Jan; 35(1):61-3. PMID: 23249961.
      View in: PubMed
    20. Marachelian A, Shimada H, Sano H, Jackson H, Stein J, Sposto R, Matthay KK, Baker D, Villablanca JG. The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma. Pediatr Blood Cancer. 2012 May; 58(5):675-81. PMID: 22493777.
      View in: PubMed
    21. DuBois SG, Chesler L, Groshen S, Hawkins R, Goodarzian F, Shimada H, Yanik G, Tagen M, Stewart C, Mosse YP, Maris JM, Tsao-Wei D, Marachelian A, Villablanca JG, Matthay KK. Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. Clin Cancer Res. 2012 May 01; 18(9):2679-86. PMID: 22421195.
      View in: PubMed
    22. Russell HV, Groshen SG, Ara T, DeClerck YA, Hawkins R, Jackson HA, Daldrup-Link HE, Marachelian A, Skerjanec A, Park JR, Katzenstein H, Matthay KK, Blaney SM, Villablanca JG. A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer. 2011 Aug; 57(2):275-82. PMID: 21671363; PMCID: PMC3117015.
      View in: PubMed, PubMed Central
    23. Khatua S, Dhall G, O'Neil S, Jubran R, Villablanca JG, Marachelian A, Nastia A, Lavey R, Olch AJ, Gonzalez I, Gilles F, Nelson M, Panigrahy A, McComb G, Krieger M, Fan J, Sposto R, Finlay JL. Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation. Pediatr Blood Cancer. 2010 Jul 15; 55(1):42-6. PMID: 20222020.
      View in: PubMed
    24. Bavishi S, Wong K, Delgardo T, Marachelian A, Khatua S. Successful radiation therapy for supratentorial primitive neuroectodermal tumor and epidermolysis bullosa simplex. Pediatr Blood Cancer. 2010 Jan; 54(1):170-2. PMID: 19760773.
      View in: PubMed
    25. Butturini AM, Jacob M, Aguajo J, Vander-Walde NA, Villablanca J, Jubran R, Erdreich-Epstein A, Marachelian A, Dhall G, Finlay JL. High-dose chemotherapy and autologous hematopoietic progenitor cell rescue in children with recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors: the impact of prior radiotherapy on outcome. Cancer. 2009 Jul 01; 115(13):2956-63. PMID: 19402050.
      View in: PubMed
    26. Marachelian A, Butturini A, Finlay J. Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for childhood central nervous system tumors. Bone Marrow Transplant. 2008 Jan; 41(2):167-72. PMID: 18176620.
      View in: PubMed
    27. Jubran RF, Marachelian A, Dorey F, Malogolowkin M. Predictors of outcome in children with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2005 Jul; 45(1):37-42. PMID: 15768381.
      View in: PubMed
    Araz's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (135) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (27) people
    _
    Similar People
    People who share similar concepts with this person.
    See all (60) people
    _
    Same Department
    Search Department
    ↑